| review article | Q7318358 |
| scholarly article | Q13442814 |
| P50 | author | Michael O. Harhay | Q37378915 |
| P2093 | author name string | Ann-Marie Sevcsik | |
| Bernard Pecoul | |||
| Fabiana Alves | |||
| Graciela Diap | |||
| Isabela Ribeiro | |||
| Robert Don | |||
| Shing Chang | |||
| P2860 | cites work | Neglected disease research and development: how much are we really spending? | Q21034357 |
| Measuring the burden of neglected tropical diseases: the global burden of disease framework | Q21144557 | ||
| The Genome Sequence of Trypanosoma cruzi, Etiologic Agent of Chagas Disease | Q22065799 | ||
| Trypanocidal drugs for late stage, symptomatic Chagas disease (Trypanosoma cruzi infection) | Q24245957 | ||
| Safety of the blood supply in Latin America | Q24557539 | ||
| A cysteine protease inhibitor cures Chagas' disease in an immunodeficient-mouse model of infection | Q24684717 | ||
| New drugs for neglected diseases: from pipeline to patients | Q24802169 | ||
| A breakthrough in R&D; for neglected diseases: new ways to get the drugs we need | Q24810470 | ||
| Structure-based approach to pharmacophore identification, in silico screening, and three-dimensional quantitative structure-activity relationship studies for inhibitors of Trypanosoma cruzi dihydrofolate reductase function | Q27650762 | ||
| The challenges of Chagas Disease-- grim outlook or glimmer of hope | Q33312506 | ||
| The neglected tropical diseases of Latin America and the Caribbean: a review of disease burden and distribution and a roadmap for control and elimination | Q33372349 | ||
| Activities of the triazole derivative SCH 56592 (posaconazole) against drug-resistant strains of the protozoan parasite Trypanosoma (Schizotrypanum) cruzi in immunocompetent and immunosuppressed murine hosts | Q33978515 | ||
| A class of sterol 14-demethylase inhibitors as anti-Trypanosoma cruzi agents. | Q34391586 | ||
| Clinical and epidemiological aspects of Chagas disease | Q34521379 | ||
| Chemotherapy of Chagas disease | Q34541660 | ||
| Trypanocidal drugs for chronic asymptomatic Trypanosoma cruzi infection. | Q34546953 | ||
| Chagas disease in Andean countries. | Q34692304 | ||
| Evaluation and treatment of chagas disease in the United States: a systematic review | Q34713358 | ||
| The impact of Chagas disease control in Latin America: a review | Q34828463 | ||
| Epidemiology of Chagas disease in non-endemic countries: the role of international migration. | Q52684308 | ||
| [Evaluation of the Chagas Disease Control Program and presence of Panstrongylus megistus in central-western Minas Gerais State, Brazil]. | Q52696993 | ||
| Nova tripanozomiaze humana: estudos sobre a morfolojia e o ciclo evolutivo do Schizotrypanum cruzi n. gen., n. sp., ajente etiolojico de nova entidade morbida do homem | Q55878589 | ||
| Efficacy of chemotherapy with benznidazole in children in the indeterminate phase of Chagas' disease | Q58842622 | ||
| [Comparative controlled study on the use of benznidazole, nifurtimox and placebo, in the chronic form of Chagas' disease, in a field area with interrupted transmission. I. Preliminary evaluation] | Q58843201 | ||
| Randomised trial of efficacy of benznidazole in treatment of early Trypanosoma cruzi infection | Q58843267 | ||
| [Natural history of Chagas disease] | Q58843613 | ||
| Long-term cardiac outcomes of treating chronic Chagas disease with benznidazole versus no treatment: a nonrandomized trial | Q58845294 | ||
| Congenital Transmission of Chagas Disease in Latin American Immigrants in Switzerland | Q59321893 | ||
| ??? | Q58842512 | ||
| Specific chemotherapy of Chagas disease: controversies and advances | Q35569069 | ||
| Virtual drug discovery and development for neglected diseases through public-private partnerships | Q35605447 | ||
| An update on Chagas disease (human American trypanosomiasis). | Q36709698 | ||
| An insight on targets and patented drugs for chemotherapy of Chagas disease. | Q37067251 | ||
| Sterol 14-demethylase inhibitors for Trypanosoma cruzi infections. | Q37118721 | ||
| Congenital transmission of Chagas disease in Latin American immigrants in Switzerland | Q37164717 | ||
| Rational modification of a candidate cancer drug for use against Chagas disease | Q37274008 | ||
| Chagas' disease as a foodborne illness | Q37436314 | ||
| Synthesis and biological evaluation of 1-amino-1,1-bisphosphonates derived from fatty acids against Trypanosoma cruzi targeting farnesyl pyrophosphate synthase | Q39502716 | ||
| Southern Cone Initiative for the elimination of domestic populations of Triatoma infestans and the interruption of transfusional Chagas disease. Historical aspects, present situation, and perspectives | Q40171092 | ||
| Emerging acute Chagas disease in Amazonian Brazil: case reports with serious cardiac involvement | Q40509059 | ||
| Cardiac involvement is a constant finding in acute Chagas' disease: a clinical, parasitological and histopathological study | Q40649314 | ||
| The protein farnesyltransferase inhibitor Tipifarnib as a new lead for the development of drugs against Chagas disease | Q40652703 | ||
| Synthesis, cytotoxicity, and antiplasmodial and antitrypanosomal activity of new neocryptolepine derivatives | Q40715553 | ||
| Kinetic characterization of squalene synthase from Trypanosoma cruzi: selective inhibition by quinuclidine derivatives | Q42112211 | ||
| Neglected diseases and poverty in "The Other America": the greatest health disparity in the United States? | Q42868433 | ||
| Chagasic cardiomyopathy in immigrants from Latin America to Spain | Q43143328 | ||
| In vitro and in vivo activities of ravuconazole on Trypanosoma cruzi, the causative agent of Chagas disease | Q44266812 | ||
| Parasitological cure of acute and chronic experimental Chagas disease using the long-acting experimental triazole TAK-187. Activity against drug-resistant Trypanosoma cruzi strains | Q44266815 | ||
| Use of polymerase chain reaction (PCR) and hybridization assays to detect Trypanosoma cruzi in chronic chagasic patients treated with itraconazole or allopurinol | Q44828624 | ||
| Geographic distribution of Triatoma dimidiata and transmission dynamics of Trypanosoma cruzi in the Yucatan peninsula of Mexico. | Q45073305 | ||
| Rationale and design of a randomized placebo-controlled trial assessing the effects of etiologic treatment in Chagas' cardiomyopathy: the BENznidazole Evaluation For Interrupting Trypanosomiasis (BENEFIT). | Q46514298 | ||
| The Trypanosoma cruzi proteome. | Q46601686 | ||
| ASAQ, a breakthrough in the fight against malaria | Q47840298 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 7 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | patient | Q181600 |
| Chagas disease | Q649558 | ||
| infectious disease | Q18123741 | ||
| P5008 | on focus list of Wikimedia project | ScienceSource | Q55439927 |
| P304 | page(s) | e484 | |
| P577 | publication date | 2009-07-07 | |
| P1433 | published in | PLoS Neglected Tropical Diseases | Q3359737 |
| P1476 | title | New, improved treatments for Chagas disease: from the R&D pipeline to the patients | |
| P478 | volume | 3 |
| Q59082746 | A new ruthenium cyclopentadienyl azole compound with activity on tumor cell lines and trypanosomatid parasites |
| Q44504229 | A new series of heteroleptic oxidovanadium(IV) compounds with phenanthroline-derived co-ligands: selective Trypanosoma cruzi growth inhibitors |
| Q64063181 | A prophylactic α-Gal-based glycovaccine effectively protects against murine acute Chagas disease |
| Q58842343 | Access to Chagas disease treatment in non-endemic countries: the case of Spain |
| Q35836581 | Access to care for Chagas disease in the United States: a health systems analysis |
| Q36702159 | Advances in Chagas disease drug development: 2009-2010 |
| Q41093486 | Aromatic amine N-oxide organometallic compounds: searching for prospective agents against infectious diseases |
| Q58701155 | Assessing the Effectiveness of Curative Benznidazole Treatment in Preventing Chronic Cardiac Pathology in Experimental Models of Chagas Disease |
| Q35023674 | Barriers to treatment access for Chagas disease in Mexico |
| Q28654673 | Bigger data, collaborative tools and the future of predictive drug discovery |
| Q52836242 | Bugging out over Chagas: Bioluminescent protozoans and old drugs might help unravel kissing-bug disease. |
| Q37717875 | Chagas Disease Diagnostic Applications: Present Knowledge and Future Steps. |
| Q41920978 | Chagas Disease Infection among Migrants at the Mexico/Guatemala Border |
| Q34315066 | Chagas disease and the london declaration on neglected tropical diseases |
| Q36933398 | Clomipramine and Benznidazole Act Synergistically and Ameliorate the Outcome of Experimental Chagas Disease |
| Q37023164 | Combination Chemotherapy with Suboptimal Doses of Benznidazole and Pentoxifylline Sustains Partial Reversion of Experimental Chagas' Heart Disease. |
| Q44083547 | Computational models for neglected diseases: gaps and opportunities |
| Q37778830 | Congenital transmission of Chagas disease: a clinical approach |
| Q47872103 | Development and in vitro/in vivo evaluation of a novel benznidazole liquid dosage form using a quality-by-design approach |
| Q28555229 | Development of Diagnostics for Chagas Disease: Where Should We Put Our Limited Resources? |
| Q61809672 | Dissecting a novel allosteric mechanism of cruzain: A computer-aided approach |
| Q36170517 | Emerging and under-recognized Chagas cardiomyopathy in non-endemic countries |
| Q37124216 | Evaluation of nifurtimox treatment of chronic Chagas disease by means of several parasitological methods |
| Q28656268 | Evaluation of spatially targeted strategies to control non-domiciliated Triatoma dimidiata vector of Chagas disease |
| Q52334618 | Expanding the toolbox for Trypanosoma cruzi: A parasite line incorporating a bioluminescence-fluorescence dual reporter and streamlined CRISPR/Cas9 functionality for rapid in vivo localisation and phenotyping. |
| Q35130398 | Follow-up of an asymptomatic Chagas disease population of children after treatment with nifurtimox (Lampit) in a sylvatic endemic transmission area of Colombia |
| Q60031608 | High Throughput and Computational Repurposing for Neglected Diseases |
| Q36278397 | Improving access to Chagas disease diagnosis and etiologic treatment in remote rural communities of the Argentine Chaco through strengthened primary health care and broad social participation |
| Q26786761 | Kinases as druggable targets in trypanosomatid protozoan parasites |
| Q28545842 | Machine Learning Models and Pathway Genome Data Base for Trypanosoma cruzi Drug Discovery |
| Q40288847 | Mutagenic and Cytotoxicity LQB 123 Profile: Safety and Tripanocidal Effect of a Phenyl-t-Butylnitrone Derivative |
| Q28548478 | Neglect of a Neglected Disease in Italy: The Challenge of Access-to-Care for Chagas Disease in Bergamo Area |
| Q35822254 | New organoruthenium complexes with bioactive thiosemicarbazones as co-ligands: potential anti-trypanosomal agents. |
| Q33955428 | Parasitic loads in tissues of mice infected with Trypanosoma cruzi and treated with AmBisome |
| Q56511193 | Pioneering Use of the Cloud for Development of Collaborative Drug Discovery (CDD) Database |
| Q46735046 | Potential mechanism of the anti-trypanosomal activity of organoruthenium complexes with bioactive thiosemicarbazones |
| Q92347304 | Purification of Glycosylphosphatidylinositol-Anchored Mucins from Trypanosoma cruzi Trypomastigotes and Synthesis of α-Gal-Containing Neoglycoproteins: Application as Biomarkers for Reliable Diagnosis and Early Assessment of Chemotherapeutic Outcome |
| Q92440258 | Rapid immunochromatographic tests for the diagnosis of chronic Chagas disease in at-risk populations: A systematic review and meta-analysis |
| Q38256874 | Recent clinical trials for the etiological treatment of chronic chagas disease: advances, challenges and perspectives |
| Q37544765 | Reversible cysteine protease inhibitors show promise for a Chagas disease cure |
| Q35738489 | Secondary kill effect of deltamethrin on Triatoma infestans |
| Q40281916 | Spatiotemporal analysis of reported cases of acute Chagas disease in the State of Pernambuco, Brazil, from 2002 to 2013. |
| Q28540817 | Synergy testing of FDA-approved drugs identifies potent drug combinations against Trypanosoma cruzi |
| Q33584473 | Ten years of Chagas disease research: Looking back to achievements, looking ahead to challenges |
| Q42592597 | The BENEFIT Trial: Where Do We Go from Here? |
| Q58571928 | The burden of congenital Chagas disease and implementation of molecular diagnostic tools in Latin America |
| Q33627688 | The centennial of the discovery of Chagas disease: facing the current challenges |
| Q38032507 | The emerging role of amiodarone and dronedarone in Chagas disease |
| Q33479112 | The unfinished public health agenda of chagas disease in the era of globalization |
| Q37879203 | Therapy of vector-borne protozoan infections in nonendemic settings |
| Q37744965 | Trypanosomiasis, cardiomyopathy and the risk of ischemic stroke |
| Q37998091 | Use of cysteine-reactive small molecules in drug discovery for trypanosomal disease |
| Q92124476 | Use of rapid diagnostic tests (RDTs) for conclusive diagnosis of chronic Chagas disease - field implementation in the Bolivian Chaco region |
| Q90743739 | Vanadium compounds in medicine |
| Q96137447 | WHF IASC Roadmap on Chagas Disease |
| Q50936607 | [Notes on rapid diagnostic tests for chronic Chagas disease]. |
Search more.